||Director of Research
Mystic, CT and Boston, MA
||Research & Development
|2006||Senior Research Fellow, Innovation and the Idea Farm|
|2004||Executive Director, Exploratory Medicinal Sciences|
|2001||Group Director, Discovery Biology|
|1998||Research Director, Chemistry|
|1994||Assistant Director, Medicinal Chemistry|
|1990||Manager, Medicinal Chemistry|
|1990||Manager, New Leads Exploratory Medicinal Biology|
|1987||Project Leader, Pharmacology|
||Research Section Leader, Institute of BioOrganic Chemistry
||University of Wisconsin, Madison, and M.I.T.
Helen Hay Whitney fellow, William H. Orme-Johnson, adviser
||Massachusetts Institute of Technology, Cambridge MA
National Science Foundation fellow, Christopher T. Walsh, adviser
||Williams College, Williamstown MA
magna cum laude, honors, Phi Beta Kappa 1972
After college, graduate school, and postdoc, I was a lab supervisor in Syntex doing mechanism-based drug design for 6 years. Moving to Pfizer, I co-invented the discipline of High Throughput Screening (HTS) and led the team that found the first non-peptidic antagonists of Substance P, bombesin, CRH, and many others. I rose through management ranks from Project Leader (1987) to Executive Director (2004), the latter with a 110-person department including all HTS, high-speed chemistry, outsourcing, & computational chemistry for Pfizer's largest research site, and served on numerous local and international management teams, several as chairman and with third-party partnerships. I've received Pfizer Global R&D's highest personal achievement award and the company's Upjohn Innovation award.
In 2006 I chose to make a lateral career move out of management, inventing and taking the unique role of full-time innovation and idea management leader for all of Pfizer's 15,000 person R&D division. As author and facilitator of over 200 business challenges in four years, I have a deep, practical, and diverse base of experience in collective approaches to business needs. My title was Senior Research Fellow, Pfizer's highest non-management position. I was also on the leadership team for Pfizer R&D's Continuous Improvement group, 2008-2010. Retired from Pfizer in 2010, I am currently the Director of Research at Imaginatik PLC, helping to bring scalable collaborative processes to major corporate clients.
I was an adjunct faculty member at the University of Toronto, and have taught in Connecticut College Medicinal Chemistry courses.
I have always had a passion for finding patterns in large sets of data and then doing something practical with those observations. I believe that important and useful things tend to be complex and cannot be oversimplified, though that complexity can be layered and managed to help implement solutions at appropriate levels. While I enjoy the academic scientist's approach (explore, discover, synthesize, publish, teach), I am a champion of the private sector as the most efficient, effective, and sustainable place to implement change. I am a micro-and-macro thinker: happy to craft strategy and processes, yet equally happy to dive into spreadsheets, algorithms, and low-level implementation, and have always found that each illuminates the other. I enjoy writing and public speaking as the details below will attest.
In the next phase of my career I aspire to bring my employer unique experience in crafting and managing large-scale collaborative innovation programs inside a Fortune 100 corporation, along with my analytical interests and software implementation skills in revealing useful patterns in large datasets.
Find me on Google